- Home
- GNTA vs PSNL Comparison
GNTA vs PSNL Comparison
Compare GNTA & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | PSNL |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 872.1M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GNTA | PSNL |
|---|---|---|
| Price | $1.45 | $8.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.71 |
| AVG Volume (30 Days) | 94.9K | ★ 1.5M |
| Earning Date | 03-30-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,103,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.28 | $2.83 |
| 52 Week High | $10.00 | $11.40 |
Technical Indicators
Market Signals| Indicator | GNTA | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 36.36 | 45.67 |
| Support Level | $1.28 | $7.68 |
| Resistance Level | $1.68 | $9.10 |
| Average True Range (ATR) | 0.18 | 0.57 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 22.78 | 26.07 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.